MedPath

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Registration Number
NCT00106821
Lead Sponsor
Boehringer Ingelheim
Brief Summary

The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of African American descent.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
166
Inclusion Criteria
  • Male or female of African descent
  • 40 years of age or older
  • Diagnosis of COPD
  • History of smoking at least one pack per day for at least 10 years
  • Currently experiencing shortness of breath at least with exertion
Exclusion Criteria
  • Asthma
  • Recent myocardial infarction or hospitalization for congestive heart failure

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The primary efficacy endpoint will be FEV1 AUC (0-3) after 8 weeks of treatment
Secondary Outcome Measures
NameTimeMethod
FEV1 AUC0-3 after single dose, 4 weeks of treatment, peak FEV1 on each test day, trough FEV1 at weeks 4 & 8, FVC trough (weeks 4 & 8), peak and AUC(0-3) (on all test days), FEV1 and FVC at all time points, rescue albuterol use, dyspnea SOP questionnaire

Trial Locations

Locations (16)

LSU MC-Sheveport

🇺🇸

Shreveport, Louisiana, United States

VAMC Houston

🇺🇸

Houston, Texas, United States

Boehringer Ingelheim Investigational Site

🇺🇸

Charleston, South Carolina, United States

Yale Univ. Pulmonary and Critical Care Medicine

🇺🇸

WEst Haven, Connecticut, United States

Louisiana State University School of Medicine

🇺🇸

New Orleans, Louisiana, United States

Spartanburg Medical Research

🇺🇸

Spartanburg, South Carolina, United States

Brody School of Medicine, East Carolina University

🇺🇸

Greenville, North Carolina, United States

David Geffen School of Medicine

🇺🇸

Los Angeles, California, United States

Cooper Green Hospital

🇺🇸

Birmingham, Alabama, United States

Emerald Coast Research Associates

🇺🇸

Panama City, Florida, United States

Bay Pines V. A. Medical Center

🇺🇸

St. Petersberg, Florida, United States

Attention: Amir Sharafkhaneh, M.D.

🇺🇸

Houston, Texas, United States

Bronx VA Medical Center

🇺🇸

Bronx, New York, United States

VA Greater Los angeles Health Care Systems

🇺🇸

Sepulveda, California, United States

Temple University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath